Q-omics provides the consensus-scored PPIP5K1 profile across patient tissues and cancer cell-line models. PPIP5K1 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, PPIP5K1 is differentially expressed in 8, with the highest sampling consensus in LIHC. Additionally, PPIP5K1 RNA expression shows 20,060 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRP, LIHC, and ACC as cancer lineages where PPIP5K1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PPIP5K1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PPIP5K1 survival associations across molecular data types. PPIP5K1 RNA expression shows survival associations in the most cancer types (17), followed by mutation status (4) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PPIP5K1 RNA expression–survival associations across cancer types. High PPIP5K1 expression shows unfavorable associations in OV, COAD and LUSC, but favorable associations in KIRP, BRCA and ACC. The KIRP Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify KIRP as the clearest survival context for PPIP5K1 RNA expression.
This table summarizes PPIP5K1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8, while mass-spec protein shows differences in 6. The strongest signals are observed in LIHC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for PPIP5K1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PPIP5K1 shows lower tumor expression in KIRC and higher tumor expression in LIHC, LUSC, LUAD, CHOL and STAD. The LIHC box plot shows higher PPIP5K1 RNA expression in tumor versus normal tissue (log2 FC = +1.121, t-test p < 0.001).
This table shows molecular features associated with PPIP5K1 in patient tissues and cancer cell lines. In patient samples, PPIP5K1 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, PPIP5K1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in LIVER and BLOOD_Leukemia.
